drugset / Trial / NCT00407641

Effects of Tinzaparin on Cardio-vascular Outcomes and on Blood Lipids in Diabetic Patients on Chronic Hemodialysis

NCT00407641

Phase 4 Withdrawn Anemia Working Group Romania
RandomizedParallel-groupSingle-blindPrevention

Summary

Low molecular weight heparin (LMWH) provides a safe and effective alternative to UFH for hemodialysis anticoagulation. While unfractionated (UF) heparin has been implicated in hyper-lipidemia, the effect of LMWHs on the lipid profile in non-diabetic patients on chronic hemodialysis remains controversial. The effect of LMWH in diabetic patients, a high risk group for developing hyper-lipidemia and cardio-vascular disease, has not been studied. The study intends to examine the long-term effects of the replacement of UFH by LMWH (tinzaparin sodium) on cardio-vascular outcomes and on lipoprotein profiles in a large group of diabetic patients stable on HD.

Timeline

Start
2009-03
Primary completion
2015-01
Completion
2017-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Heparin Other / unclassified
Subject Tinzaparin Other / unclassified

Indications